Encouraging Trial Results for Hep C Drug Faldaprevir
Share
Follow Us
The Editors at Hepatitis Central
May 2, 2013
Data from Boehringer Ingelheim’s Phase III trial of faldaprevir claims high success rates for treatment-naïve patients with Hepatitis C genotype 1.
Boehringer Ingelheim reports positive data from hepatitis drug trial
25 April 2013 11:01 in Pharmaceutical Company Product News
Boehringer Ingelheim has reported positive results from STARTVerso 1, a phase III trial evaluating the benefits of the new hepatitis C treatment faldaprevir.
Data from the study showed that the new once-daily protease inhibitor was able to deliver high viral cure rates and early therapy success among treatment-naive patients with genotype 1 hepatitis C infections.
Continue reading this entire article:
http://www.zenopa.com/news/801576832/boehringer-ingelheim-reports-positive-data-from-hepatitis-drug-trial
